跳至主要内容
临床试验/JPRN-jRCTs051180111
JPRN-jRCTs051180111已完成2 期

Evaluation of the efficacy of Sofosbuvir and Ribavirin in children with genotype 2 hepatitis C virus infection

Tajiri Hitoshi0 个研究点目标入组 1 人开始时间: 2019年3月11日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
1

研究概览

简要总结

Combination therapy of sofosbuvir and ribavirin was safe and effective in the single case with genotype 2 chronic hepatitis C.

研究设计

研究类型
Interventional

入排标准

年龄范围
12age 至 18age(—)
性别
All

入选标准

  • 1. Patients who are visiting the department of Pediatrics or being admitted in our institute.
  • 2. Patients with age 12 and 18 years at the agreement acquisition.
  • 3. HCV genotype-2 infection.
  • 4. Written informed consent after adequate explanation and acceptance.

排除标准

  • 1. Patients with a suspicion of cirrhosis by blood examination or imaging studies.
  • 2. Patients who is diagnosed as liver cirrhosis by pathological examination.
  • 3. Patients with hepatocellular carcinoma.
  • 4. Patients with poor adherence of medicine.
  • 5. Patients who have any underlying disorders which can be affected by the treatment.
  • 6. Patients who are assessed to be ineligible for this study by the principle investigator.

研究者

发起方
Tajiri Hitoshi

相似试验